Nanjing Vazyme Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	-	434.25	1,967	1,545	1,478
Trading Asset Securities	-	2,222	1,514	1,719	1,976
Cash & Short-Term Investments	2,721	2,656	3,481	3,264	3,454
Cash Growth	2.45%	-23.69%	6.65%	-5.49%	239.50%
Accounts Receivable	-	483.61	351.93	839.62	322.32
Other Receivables	-	20.81	4.07	7.72	4.67
Receivables	-	504.42	356.01	847.35	326.99
Inventory	-	362.18	346.25	364.2	242.19
Prepaid Expenses	-	0.05	-	-	-
Other Current Assets	-	48.58	47.12	89.71	28.1
Total Current Assets	-	3,571	4,230	4,565	4,051
Property, Plant & Equipment	-	726.07	767.3	679.48	308.98
Long-Term Investments	-	54.83	47.3	22.31	18.48
Goodwill	-	130.49	130.49	130.49	-
Other Intangible Assets	-	95.19	101.24	49.7	16.65
Long-Term Accounts Receivable	-	0.15	-	-	-
Long-Term Deferred Tax Assets	-	146.04	106.51	67.12	24.87
Long-Term Deferred Charges	-	278.91	280.54	318.31	145
Other Long-Term Assets	-	45.51	82.53	172.69	42.25
Total Assets	-	5,049	5,746	6,005	4,607
Accounts Payable	-	90.4	146.82	318.78	118.76
Accrued Expenses	-	129.74	112.52	258.07	104.7
Short-Term Debt	-	551.32	1,134	272.21	-
Current Portion of Leases	-	57.03	46.16	58.25	31.25
Current Income Taxes Payable	-	0.6	0.03	0.54	20.02
Current Unearned Revenue	-	54.87	55.92	214.55	95.03
Other Current Liabilities	-	19.36	24.09	31.67	17.5
Total Current Liabilities	-	903.33	1,520	1,154	387.26
Long-Term Leases	-	143.36	106.89	127.68	59.93
Long-Term Unearned Revenue	-	48.38	21.38	19.25	16.24
Long-Term Deferred Tax Liabilities	-	1.26	1.51	11.19	0.87
Other Long-Term Liabilities	-	8.72	67.6	80.92	15.52
Total Liabilities	-	1,105	1,717	1,393	479.83
Common Stock	-	402.13	400.01	400.01	400.01
Additional Paid-In Capital	-	2,512	2,442	2,429	2,422
Retained Earnings	-	1,139	1,209	1,780	1,305
Treasury Stock	-	-104.4	-20.01	-	-
Comprehensive Income & Other	-	-3.97	-1.72	-	-
Total Common Equity	3,844	3,945	4,029	4,609	4,127
Minority Interest	-	-1.63	-0.11	3.2	-
Shareholders' Equity	3,841	3,944	4,029	4,612	4,127
Total Liabilities & Equity	-	5,049	5,746	6,005	4,607
Total Debt	861.49	751.71	1,287	458.14	91.18
Net Cash (Debt)	1,860	1,905	2,194	2,806	3,362
Net Cash Growth	-2.35%	-13.19%	-21.81%	-16.56%	230.91%
Net Cash Per Share	4.38	5.26	5.57	7.03	9.27
Filing Date Shares Outstanding	704.74	397.82	397	400.01	400.01
Total Common Shares Outstanding	704.74	397.82	397	400.01	400.01
Working Capital	-	2,668	2,711	3,411	3,664
Book Value Per Share	10.49	9.92	10.15	11.52	10.32
Tangible Book Value	3,624	3,720	3,798	4,429	4,111
Tangible Book Value Per Share	9.89	9.35	9.57	11.07	10.28
Machinery	-	712.88	656.11	513.97	250.31
Construction In Progress	-	69.42	127.48	69.44	-

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.